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Abstract
Tumor vasculature is an attractive therapeutic target
as it differs structurally from normal vasculature, and
the destruction of a single vessel can lead to the death
of many tumor cells. The effects of antivascular drugs
are frequently short term, with regrowth beginning
less than 24 hours posttreatment. This study inves-
tigated the duration of the response to the vascular
targeting agent, ZD6126, of the GH3 prolactinoma, in
which efficacy and dose–response have previously
been demonstrated. GH3 prolactinomas were grown in
the flanks of eight Wistar Furth rats. All animals were
treated with 50 mg/kg ZD6126. The tumors were
examined with dynamic contrast–enhanced magnetic
resonance imaging (DCE-MRI) 24 hours pretreatment
and posttreatment, and at a single time between 48 and
96 hours posttreatment. No evidence of recovery of
perfusion was observed even at the longest (96-hour)
time point. Involvement of a statistician at the project
planning stage and the use of DCE-MRI, which permits
noninvasive quantitation of parameters related to
blood flow in intact animals, allowed this highly
significant result to be obtained using only eight rats.
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Introduction
In order to survive and grow, solid tumors need to maintain
a functional vascular network. However, tumor blood ves-
sels differ significantly from vessels in normal tissues,
making tumor vasculature an important target for therapeu-
tic intervention in cancer [1]. Vascular targeting aims to
exploit these differences to selectively destroy tumor vas-
culature, irreversibly arresting blood flow to tumors. This
induces tumor ischemia, leading to a rapid cell death by
necrosis throughout central areas of the tumor normally
considered resistant to conventional therapies. Character-
istically, in experimental tumor models, a thin viable rim of
tumor cells is seen to survive following treatment with
vascular targeting agents. To explain this, it has been hypoth-
esized that nontumor blood vessels in the surrounding tissues
provide essential nutrients and oxygen, allowing tumor cells at
the rim to survive the destruction of blood vessels throughout
the tumor. Because the surviving rim of tumor is likely to be well
perfused by surrounding vessels in normal tissues, the addition
of other therapeutic modalities, such as chemotherapy and
radiotherapy, may be particularly effective when combined with
vascular targeting agents.
One vascular targeting approach has been to disrupt the
proliferating, immature endothelial cells found selectively in
tumor microvasculature compared with normal tissue micro-
vasculature. Proliferating endothelial cells appear to rely on a
microtubular cytoskeleton to maintain cell shape and, there-
fore, vessel function, and microtubule-destabilizing agents
such as colchicines and the Vinca alkaloids have demonstrated
vascular targeting activity against tumor blood vessels. How-
ever, these effects were only seen close to the maximum
tolerated dose, and direct tumor cell killing through G2/mitotic
arrest is likely to be the dominant mode of the antitumor action
of these tubulin-binding agents.
Disruption of tumor blood vessel function by vascular targeting
agents is a rapid event occurring within hours of drug treatment.
Therefore, it has been proposed that the most effective vascular
targeting agents will have rapidly reversible tubulin-binding kinet-
ics, and a relatively rapid clearance in vivo, potentially mini-
mizing direct cytotoxicity to tumor cells and normal tissues.
N-acetylcolchinol-O-phosphate (ZD6126) is a novel vascu-
lar targeting agent that in mouse allograft and xenograft models
demonstrated rapid clearance in vivo (1–2 hours), with signif-
icant inhibition of both tumor blood flow and induction of
massive central tumor necrosis (at ZD6126 doses of one
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thirtieth and one eighth of the maximum tolerated dose,
respectively) [2,3]. It has also been shown to have significant
antitumor activity in a mouse lung cancer metastasis model
[4]. In addition, ZD6126 was also shown to induce rapid and
reversible microtubule destabilization and cell shape change
in endothelial cells in vitro. These studies have shown that
the activity profile of ZD6126 is consistent with a vascular
targeting, rather than a cytotoxic, mechanism.
A single dose of ZD6126 consistently induced mas-
sive central necrosis in a range of histologically diverse
xenograft/allograft tumor models, although this did not
always translate to tumor shrinkage, presumably due to
regrowth from the remaining rim of viable tumor cells.
Measuring necrosis histologically is a useful objective
measure of drug response in preclinical models, but it
has two significant drawbacks. As a preclinical tool, it is
inefficient as the animal in which the tumor is grown must
be sacrificed to perform the measurement, requiring many
more animals than techniques where serial studies on a
single animal are possible. Moreover, measuring necrosis
is unlikely to provide a useful clinical measure of tumor
response due to the heterogeneity of tumors and the
sampling errors inherent in biopsy assessment. A nonin-
vasive functional imaging technique that provides a quan-
titative endpoint is clinically translatable and permits serial
studies, allowing reduction of animal usage. Magnetic
resonance imaging (MRI) has been used to investigate
the effects of ZD6126, both in animal models and in Phase I
clinical trials. The majority of these studies have used
dynamic contrast–enhanced magnetic resonance imaging
(DCE-MRI). This can be analyzed with one of a number of
compartmental models, giving a value for the transfer
constant of a contrast agent from blood plasma to the
extravascular extracellular space, or more simply by mea-
suring the integrated area under the [gadolinium]– time
curve (IAUGC). A high value of IAUGC may reflect high
blood flow, high vascular volume, high interstitial fraction,
and/or high endothelial permeability. The dramatic reductions
in tumor perfusion that are observed after treatment with
antivascular agents are therefore reflected in substantial
reductions in the DCE-MRI parameters. Robinson et al. [5]
performed a dose–response study using DCE-MRI in GH3
prolactinomas in rats, and showed highly significant changes
in the fraction of the tumor that enhanced strongly 24 hours
posttreatment with 25 or 50 mg/kg ZD6126, but no significant
response at 12.5mg/kg ZD6126; this study also demonstrated
significant changes in the relaxation time T2* measured by
multigradient echo MRI in GH3 prolactinomas and dose-
dependent increases in the necrotic fraction measured by
histology. Evelhoch et al. [6] used DCE-MRI to evaluate the
effects of ZD6126 in C38 colon adenocarcinomas in mice
and, subsequently, in metastatic liver disease in patients
receiving ZD6126 as part of a Phase I clinical trial [7]. In the
human studies, IAUGC was reduced in five of six patients at
6 hours after treatment and in two of six patients at 18 to
21 days posttreatment. The murine studies revealed highly
significant changes in IAUGC at doses of 100 or 200 mg/kg
ZD6126, but no significant change at 50 mg/kg. Goertz et al.
[8] used high-frequency (25–38 MHz) Doppler ultrasound to
examine changes in blood flow in MeWo melanomas grown
subcutaneously in nude mice pretreatment and posttreat-
ment with 20 mg/kg ZD6126. Substantial drops in perfusion
were observed at 4 hours posttreatment, with recovery by
24 hours. Histological perfused vessel counts based on
Hoechst 33342 were consistent with the ultrasound data.
These previous functional imaging studies have assessed
the dose response of experimental tumors 24 hours post-
treatment as observed by DCE-MRI, and demonstrated a
significant correlation between tumor necrosis and DCE-
MRI. Similar correlations between histologically measured
necrosis and DCE-MRI parameters have also been demon-
strated in human pediatric osteosarcoma after treatment with
ifosfamide and carboplatin [9], and Ewing and osteogenic
sarcomas after treatment with cyclophosphamide, doxorubi-
cin, and vincristine, and methotrexate, cisplatin, and doxo-
rubicin, respectively [10].
Regrowth of viable tumor after ZD6126 treatment has, to
date, been assessed only by histological studies of treated
tumors, which have shown that regrowth can occur within a
few days of treatment [2,3]. The objective of the present
study, therefore, was to explore the time course of recovery
of perfusion, as evidenced by IAUGC analysis, following the
expected [5] acute drop in perfusion at 24 hours posttreat-
ment. The experimental design was selected in order to
explore the broadest recovery time window (48–96 hours
postdose) with the minimum number of animals. Each animal
was used as its own control and imaged at baseline
(24 hours before dosing), 24 hours after dosing, and n hours
postdosing (where n = 48, 60, 72, or 96). It was considered
undesirable to expose any animal to more than three bouts of
anesthesia during the study. The design included two ani-
mals in each of four time points in order to provide more
informative data rather than using a single n time point and
allowing the half-time of a linear recovery in highly enhancing
fraction (HEF) to be estimated.
Methods
All experiments were performed in accordance with the UK
Home Office Animals Scientific Procedures Act 1986. GH3
prolactinomas were grown subcutaneously in the flanks of
eight Wistar Furth rats [11]. Tumor volume was measured
using calipers, assuming an ellipsoidal shape. The mean
tumor volume at the first MRI scan was 1.71 ± 0.2 cm3
(mean ± standard error of the mean, range 0.95–2.47 cm3).
Anesthesia was induced with 4 ml/kg fentanyl citrate
(0.315 mg/ml) plus fluanisone (10 mg/ml) (Hypnorm;
Janssen Pharmaceutica NV, Beerse, Belgium), midazolam
(5 mg/ml) (Hypnovel; Roche, Basil, Switzerland), and water
(1:1:2) injected intraperitoneally. This anesthetic mixture has
been shown to have a minimal effect on tumor blood flow
[12]. The imaging study lasted 90 minutes from administra-
tion of anesthetic.
Formulation, Administration, and Dosing of ZD6126
ZD6126 was formulated in 20% of 5% sodium carbon-
ate and 80% phosphate-buffered saline, yielding a clear
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solution at fpH 7, and was administered intravenously as
a bolus injection through a tail vein. All animals were
treated with 50 mg/kg ZD6126. This dose has previously
been demonstrated to be well tolerated and to have a large
statistically significant effect on tumor necrosis and DCE-
MRI HEF in this host and tumor model [5].
DCE-MRI
Dynamic contrast–enhanced MRI (DCE-MRI) was per-
formed three times on each rat: 24 hours pre– and post–
ZD6126 treatment in each animal, and at one additional time
point of 48, 60, 72, or 96 hours posttreatment (n = 2 per time
point). MRI data were acquired on a Varian Unity Inova 4.7T
horizontal bore system with 14 G/cm gradients of rise time of
250 microseconds and inner diameter of 154 mm. The
radiofrequency coil used was a quadrature birdcage coil,
which enclosed the rats from the neck to the base of the tail.
For all images, the field of view was 60 mm, slice thickness
was 2 mm, and resolution was 128  128 points, giving an
in-plane resolution of 0.47 mm. One signal average was
acquired per phase-encoding step for all images except for
the T2-weighted images, for which two signal averages were
acquired to enhance the signal-to-noise ratio. Prior to con-
trast agent administration, T1-weighted spin-echo images
were obtained with echo time TE = 10 milliseconds and
repetition times TR of 0.12, 0.5, 2, and 10 seconds to enable
accurate calculation of the native tissue T1 value. Four
contiguous sagittal slices covering the full volume of the
tumor were selected together with one transverse slice
through the abdomen to provide a normal tissue reference
from paraspinal muscle. T2-weighted spin-echo images
(TE = 120 milliseconds, TR = 3000 milliseconds) were also
obtained from the same slices to facilitate definition of the
tumor boundaries. The slice positions for the posttreatment
scans were registered as closely as possible with the pre-
treatment scans for optimum comparison of the pretreatment
and posttreatment DCE-MRI values. Multislice DCE-MRI
data were then acquired using a spin-echo sequence
(TR = 120 milliseconds, TE = 10 milliseconds, resulting in
a time resolution of 15.4 seconds). Five image sets were
acquired prior to injection of 0.1 mmol/kg gadodiamide
(Omniscan; Nycomed Amersham Imaging) and 40 image
sets postinjection, giving a total imaging time postinjection of
10 minutes and 15 seconds. The five preinjection image sets
were averaged prior to DCE-MRI data processing to en-
hance the baseline signal-to-noise ratio and hence the
precision of the tissue [gadodiamide] calculation, which
depends on the change in signal from the baseline level.
After the third MRI examination, each rat was euthanized
by cervical dislocation while still anesthetized. The tumors
were immediately excised, fixed in formal saline, sliced
parallel to the MRI plane, and stained with hematoxylin and
eosin (H&E). Tissue sections were assessed for necrosis,
using a scale from grade 1 (0–10% necrosis) to grade
10 (> 90–100% necrosis) [2]. The necrosis scores represent
the median value of between three and five sections for
each tumor.
Tumor Growth Delay Studies
Sacrificing the group of rats undergoing MRI immediately
after the last imaging session in order to confirm necrosis
histologically prevented growth delay assessment. There-
fore, growth delay studies were performed in a second cohort
of animals in which all animals were studied for 96 hours
posttreatment. Tumor volume was measured as before.
Measurement was performed at 24-hour intervals from 0 to
168 hours postadministration of 50 mg/kg ZD6126 (n = 3) or
saline vehicle for control (n = 3).
DCE-MRI data were analyzed using an IAUGC method
[13,14], implemented in IDL 5.3/5.4 (Research Systems,
Boulder, CO). Tumor data were calculated from all four
slices, except where the tumor was too small to occupy all
slices. Regions of interest (ROIs) were drawn around tumor
and a reference tissue in the paraspinal muscle by a single
blinded observer using manual segmentation. In order to
investigate whether there was a difference in tumor response
between the center and the periphery of the tumor [15,16],
ROIs were automatically generated from the manually drawn
tumor ROIs to segment the tumor into a core region and a rim
of thickness 3 mm (Figure 1). Absolute values of IAUGC of
reference tissues pretreatment and posttreatment were test-
ed for systematic changes in response to treatment using
paired two-sample t-test, and no significant effect was found
(P = .66 for pretreatment versus the 24-hour time point and
P = .41 for pretreatment versus the final time point in each
animal). The concentration of gadodiamide was calculated in
each voxel within the ROI from the change in the T1 relax-
ation time using a value of 3.8 mM1 sec1 for the relaxivity
of gadodiamide. The IAUGC was calculated from the integral
of the first 10 images, representing 153 seconds postcon-
trast administration. The IAUGC was normalized by division
by the median value of the normal tissue in order to com-
pensate for variations in the contrast agent arterial input
function between animals. Voxels were defined to be highly
enhancing where the normalized value was greater than 1.
This choice of limit was made to define regions of tumor that
did not enhance substantially, rather than to distinguish
tumor from normal tissues. The choice was supported by
cumulative histogram analysis of the data. The HEF is a
Figure 1. Examples of the ROIs selected for a single slice through the tumor
grown in rat B 72 hours posttreatment with ZD6126. The images are of
IAUGC. (A) Whole-slice ROI. Pixels outside the manually drawn ROIs have
been set to black. IAUGC images of (B) an automatically generated rim ROI
of thickness 3 mm and (C) the core ROI consisting of voxels at least 3 mm
from the tumor surface. In (B) and (C), the core and rim ROIs, respectively,
have been cross-hatched to help distinguish the limits of the ROI images.
Note that posttreatment, IAUGC is very low in the bulk of the core.
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proxy for the vascularized tumor volume [5]. The Wilcoxon
signed rank statistic was used to analyze the changes in HEF
at different time points.
Results
IAUGC Analysis
The HEF was high (between 0.73 and 0.96, mean ±
standard deviation 0.85 ± 0.1) for all animals at baseline.
All tumors showed a significant reduction overall in HEF
24 hours posttreatment (mean 46%, Wilcoxon signed rank
statistic S = 18, P = .008, two-sided), but there was
considerable interanimal variability in the response (range
23–96% reduction in HEF, mean ± standard deviation
0.45 ± 0.2). Previous studies [5] show that vehicle-treated
GH3 tumors do not show a significant reduction in HEF
due to spontaneous necrosis at this time point, even at a
larger volume than those studied in this work. As shown in
Figure 2A, there was no evidence of any trend to recovery
in perfusion even at the latest time point of 96 hours
(median difference 0.004, Wilcoxon signed rank statistic,
S = 5, P = ns). No half-time for recovery of perfusion can
be estimated from these data, as it would far exceed the
time window of the experiment. The whole-tumor results
are summarized in Table 1. Generally similar results are
observed when the tumor data are segmented into rim
(Figure 2B) and core (Figure 2C) regions, with all tumor
cores and rims showing significant reduction in HEF.
However, the reduction is smaller for the rims than for
the cores (mean reduction 60% for cores and 35% for rims,
Wilcoxon signed rank statistic S, = 18, P = .008 for both).
There is no overall trend of recovery in perfusion at the
final time point in either rims or cores (Wilcoxon signed
rank statistic S = 5 (rims), S = 0 (cores), P = ns in each
case). However, the rim values plotted in Figure 2B are
consistent with a trend to earlier recovery associated with
higher values of HEF at 24 hours posttreatment.
Example data are presented as IAUGC images (Figure 3,
A–C) and histograms (Figure 3, D–F ) for rat B, which was
monitored until 72 hours posttreatment. The histograms are
generated from all four tumor image slices. The HEF is
equivalent to the proportion of the histogram above the point
where the normalized IAUGC = 1. Image voxels outside the
ROI drawn around the tumor are set to black. The pretreat-
ment image is somewhat heterogeneous, the dark regions
corresponding presumably to hypoperfused or necrotic
areas where there is poor blood flow. At 24 hours posttreat-
ment, a heterogeneous response is observed. The IAUGC is
reduced close to zero over a large proportion of the tumor.
Some regions are spared, with contrast enhancement of
similar magnitude to that pretreatment being limited to the
rim and a fraction of the core. At 72 hours, there is no sign
of recovery, and the enhancing rim appears smaller. This
is reflected in the IAUGC histogram distributions; overall
(Figure 3D), the distribution changes dramatically with treat-
ment. No substantial change is observed between 24 and 72
hours posttreatment, either overall or within the rim or core
alone. The rim (Figure 3E ) shows relatively little change on
treatment; the shape of the histogram alters, with more
voxels at very low IAUGC. However, the distribution is not
greatly altered at normalized IAUGC values above 2. The
distribution change on treatment is most dramatic in the core
(Figure 3F ), with the majority of the voxels being found in the
spike at low IAUGC.
Histology
The mean tumor necrosis score on excision was 8.3 ± 0.6
(mean ± SEM). The necrosis score was not correlated with
time from treatment (Kendall tau b = 0.23, P = .44), which
is consistent with the absence of recovery observed by
DCE-MRI. The tumor necrosis score after ZD6126 treat-
ment, at all time points from 48 to 96 hours posttreatment, is
Figure 2. (A) HEF of tumor voxels pretreatment and at two time points
posttreatment with 50 mg/kg ZD6126. The HEF for each tumor is calculated
from all four image slices. (B) HEF of voxels within the tumor rim (thickness
3 mm). (C) HEF of voxels within the tumor core, defined as regions at least
3 mm from the surface of the tumor.
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significantly correlatedwith theHEF (Kendall Tau b =0.714,
P = .0133) measured in each tumor immediately prior to
excision and histology. Necrosis score is plotted against HEF
in Figure 4. No data were acquired from animals treated with
vehicle alone in this study. Generally, the central portions of
the tumor were necrotic and viable regions were restricted to
the rim portions, reflecting the vascularized regions visible in
the IAUGC images. An example of a tumor section stained
with H&E 72 hours posttreatment is presented in Figure 5.
Tumor Growth Delay
Tumor volumes for treated and control groups are pre-
sented in Figure 6. The doubling time for the control group
was 3.75 ± 0.24 days. There was no change in the volume
of the treated tumors between days 0 and 7 (paired t-test,
t = 0.5639, P = .6296), which is consistent with the MRI
findings.
Discussion and Conclusions
Previous preclinical studies have shown that a single dose of
ZD6126 causes extensive central tumor necrosis in a range
of histologically diverse experimental tumors, leaving a char-
acteristic viable rim. The acute response observed by DCE-
MRI in this study is consistent with this response to ZD6126
as measured by MRI or histology [2,3,5,6]. Despite the
induction of widespread central tumor necrosis, a single
dose of ZD6126 does not induce prolonged tumor growth
delays as regrowth from the remaining viable rim can be
rapid. Hence, single doses of tubulin-binding tumor antivas-
cular agents in isolation result in small, unsustained growth
delays in many tumor models. Davis et al. [3] show unsus-
tained growth delay in FaDu and CaNT tumors treated with a
single dose of ZD6126, and Blakey et al. [2] show unsus-
tained growth delay in Hras5, 5.7 days of growth delay in
Calu-6, and 15.2, 12.8, and 9.4 days of growth delay in three
independent experiments on LoVo tumors treated with
ZD6126. Considerably greater growth delays result from
the use of multiple doses of ZD6126, or its use in combina-
tion with certain cytotoxic therapies such as cisplatin [2] or
radiotherapy [17].
At the outset of this study, our hypothesis was that
recovery of perfusion as evidenced by increases in HEF
after an initial reduction 24 hours after a single dose of
ZD6126 would be evident by 96 hours postdosing. This
hypothesis is not supported by the data, which provide no
evidence at all for any recovery of perfusion. Moreover, there
was good agreement between MRI-derived assessments of
HEF and histological assessment of necrosis, indicating that
our MRI measurements detect physiologically relevant per-
fusion. The 50-mg/kg necrosis scores are consistent with
those in a previous study in the GH3 prolactinoma [5], where
the necrosis scores were 4.3 ± 0.6 for the vehicle-treated
group and 8.8 ± 1.0 for the 50 mg/kg ZD6126–treated group.
Notably, the posttreatment scores are similar even though
the tumors were excised for histology 24 hours posttreat-
ment in the previous study and 48 to 96 hours posttreatment
in the present regrowth study. We have not precisely quan-
tified the growth delay in this study. However, the absence of
any change in volume in the growth delay study treated
group up to 7 days, combined with the histology and MRI
data, suggests that the effect of ZD6126 is remarkably
prolonged in this tumor model compared to other literature
values. It is not yet known what determines the tumor
regrowth rate posttreatment, although the doubling time of
the untreated tumor is likely to be a contributing factor. It is
particularly remarkable that none of the treated tumors
shows regrowth, despite the wide range of response mea-
sured by changes in HEF. The acute response does resem-
ble that of other models, with massive central necrosis but
a residual viable rim after ZD6126 treatment.
The strong inverse correlation between the HEF mea-
sured by DCE-MRI and necrosis score previously demon-
strated in the dose–response study [5] is again evident in
this study (Figure 4). However, in one case, the necrosis
score is much larger than the region of reduced flow. This
is reasonable, as cutting off blood flow must cause necro-
sis due to the removal of oxygen and nutrient supplies, but
necrosis need not result only from the loss of blood supply.
It is also possible that this necrosis results from regions
where the blood supply was transiently interrupted by the
action of ZD6126, but was restored less than 24 hours
posttreatment. Prise et al. [18] investigated the effects of a
Table 1. HEF from IAUGC analysis, change in HEF 24 hours posttreatment, and necrosis score for tumors in individual rats (A) – (H).






Time of Final HEF/Hours
Posttreatment
Final HEF Tumor Necrosis Score
A 0.959 0.035 0.924 48 0.000 10
B 0.872 0.484 0.388 72 0.497 6.5
C 0.957 0.668 0.289 60 0.677 7
D 0.766 0.590 0.176 72 0.685 6
E 0.941 0.720 0.221 96 0.750 9
F 0.772 0.424 0.348 60 0.323 9.5
G 0.774 0.263 0.511 96 0.145 9.5
H 0.732 0.451 0.281 48 0.434 9
Tumors were excised and fixed for histology immediately after the final MRI scan. Necrosis was assessed on a scale from 1 to 10, where grade 1 represents 0% to
10% necrosis, and 10 represents 90% to 100% necrosis. Necrosis scores are the median values for three to five sections for each tumor.
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single dose of combretastatin A-4 phosphate (another
class of vascular targeting agent that destabilizes micro-
tubules) on necrosis and blood flow measured by autora-
diography in the rat P22 carcinosarcoma up to 96 hours
posttreatment. They observed greater reductions in perfu-
sion in the center of the tumor compared to the periphery.
Substantial recovery occurs by 24 hours posttreatment and
the reductions are not statistically significant after this time
point. They also observe that at 96 hours posttreatment,
the region of reduced flow extends beyond the region of
necrosis, which is not the case at 24 hours. Galbraith et al.
[16] observed significantly greater reductions in DCE-MRI
in the core than in the rim of P22 carcinosarcomas 1 to 6
hours after treatment with 30 mg/kg combretastatin A-4
phosphate. They detected significant reductions in tumor
Ktrans in patients receiving combretastatin A-4 phosphate
doses of 52 mg/m2 or above as part of a Phase I clinical
trial. In 6 of 14 patients showing reduction in tumor Ktrans,
the reduction was observed to be greater in the core of the
tumor than at its periphery. These results are broadly
consistent with those obtained in the GH3 prolactinoma
with DCE-MRI post–ZD6126 treatment.
In this study, the mean HEF 24 hours posttreatment
was 0.45 ± 0.2 (mean ± SD), whereas a previous dose–
response study in the GH3 prolactinoma [5] found a value of
0.23 ± 0.2 at the same dose of 50 mg/kg ZD6126. It is
interesting to note that the volumes of the tumors in this
study (range 0.95–2.47 cm3) are smaller than those in
the earlier dose–response study (range 2.54–5.38 cm3),
and that the necrosis induced by tubulin-binding tumor
Figure 3. Images of tumor IAUGC (A) pretreatment, (B) 24 hours posttreatment, and (C) 72 hours posttreatment with ZD6126. (D) Histograms of overall tumor
IAUGC. Pretreatment, the distribution is approximately normal. Posttreatment, a dramatic shift to a bimodal distribution is observed. A large, narrow spike at low
IAUGC corresponds to the proportion of tumor that does not enhance with contrast, or enhances very slowly. The residual enhancing vascularized portion forms a
broad distribution of similar width to the pretreatment fraction. There is little change between 24 and 72 hours posttreatment. (E) Histograms of tumor rim. The
change with treatment is small compared with that in the core. (F) Histograms of tumor core. Note the very high proportion of voxels in the low IAUGC spike
posttreatment.
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antivascular agents including ZD6126 [19] and combretas-
tatin [20] has been observed to increase with tumor
volume.
The response of the tumors in this study has been
evaluated using growth curves, DCE-MRI, and histological
staining for necrosis, with consistent results. For this fast-
growing preclinical model, the tumor volume clearly shows
the growth retardation resulting from drug treatment, but
gives no information on the localization of the tumor necrosis,
or on the degree of reperfusion taking place before this is
reflected in volume increases. Volume measurements may
be of limited use in a clinical setting, where the cytostatic
nature of the effects of antivascular agents may not lead to a
reduction in tumor volume. Histology allows localization of
the tumor necrosis, but requires the sacrifice of the animal.
The noninvasive MRI exam can be repeated several times in
safety, and the IAUGC method used has been recommen-
ded as a method of choice for investigation of antivascular
and antiangiogenic agents [21]. In this preclinical study,
statistical power is greatly increased by the serial nature of
the study, which permits the use of paired statistical tests.
This study therefore provides a good example of the advan-
tages of noninvasive imaging with careful experimental
design, by using each animal as its own control, for extract-
ing significant pharmacological information from small numb-
ers of animals even in the presence of substantial interanimal
variability.
In summary, we have demonstrated that a single dose of
ZD6126 reduces perfusion for more than 96 hours in the
GH3 prolactinoma grown in Wistar Furth rats, which is longer
than the duration of reduced perfusion seen in other rodent
tumor models. This result has been obtained with a method
that is serially repeatable (allowing reduction in animal use)
and translatable to the clinic.
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